The 10-second takeaway
For the quarter ended Dec. 31 (Q1), SurModics missed slightly on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue contracted significantly and GAAP earnings per share increased.
Margins increased across the board.
SurModics booked revenue of $11.9 million. The three analysts polled by S&P Capital IQ predicted a top line of $12.2 million on the same basis. GAAP reported sales were 21% lower than the prior-year quarter's $15.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.11. The three earnings estimates compiled by S&P Capital IQ forecast $0.14 per share on the same basis. GAAP EPS were $0.15 for Q1 versus -$0.36 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 56.1%, 1,340 basis points better than the prior-year quarter. Operating margin was 27.0%, 1,870 basis points better than the prior-year quarter. Net margin was 22.7%, 6,340 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $12.5 million. On the bottom line, the average EPS estimate is $0.16.
Next year's average estimate for revenue is $50.2 million. The average EPS estimate is $0.60.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 68 members out of 89 rating the stock outperform, and 21 members rating it underperform. Among 29 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 23 give SurModics a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on SurModics is outperform, with an average price target of $16.05.
The healthcare investing landscape is littered with also-rans and a few major winners. Is SurModics the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add SurModics to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.